Physician profile
Paul D Ryan
NPI 1497750749
$1,043.14
in general payments reported to CMS, 2019-2025
10 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2021: $191 · 2022: $148 · 2023: $83.59 · 2024: $165 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $265.36 | 2022-2025 | Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $256.58 | 2023-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.36 | 2019 | |
| Shockwave Medical, INC | $119.30 | 2021 | |
| Edwards Lifesciences Corporation | $103.22 | 2024 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $71.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.78 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $25.79 | 2019 | |
| Abbott Laboratories | $24.04 | 2024 | Cardiomems |
| Amgen INC. | $17.88 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.